Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03793439 · ClinicalTrials.gov registry record · Phase 1
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03793439 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 5 participants.
The verdict
NCT03793439, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary endpoint for this study is a 50% or greater reduction in corticosteroid requirement.
Interventions
- DRUG Corticosteroid
- DIAGNOSTIC_TEST Spirometry
- DRUG Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial
- GENETIC RNA Sequencing
- DIAGNOSTIC_TEST Laboratory testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03793439
The ClinicalTrials.gov registry entry for NCT03793439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Corticosteroid is the first listed.
NCT03793439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03793439 about?
NCT03793439 is a clinical study titled "Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis". This is a pilot study to determine whether further research is warranted to assess whether tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary endpoint for this study is a 50% or greater reduction in corticosteroid requirement.
What is the current status of trial NCT03793439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-05-15. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03793439?
The interventions under investigation include: Corticosteroid (DRUG), Spirometry (DIAGNOSTIC_TEST), Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial (DRUG), RNA Sequencing (GENETIC), Laboratory testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03793439?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.